SEAPORT THERAPEUTICS INC
SPTXNASDAQTrading Snapshot
- Day Range
- $20.48 β $22.09
- 52-Week Range
- $14.85 β $28.38
- Volume (shares)
- 272,147
- Avg Volume (shares)
- β
- Shares Outstanding
- 53.5M
- Next Earnings
- 2026-11-02
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- β
- P/E Ratio
- -12.4
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.64
- Dividend Yield
- 0.00%
SEAPORT THERAPEUTICS INC
SPTXFinancial history unavailable.
StockOtter Β· stockotter.spaceAbout SEAPORT THERAPEUTICS INC
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
Seaport Therapeutics: Borrowed Efficacy, Engineered Safety, And A Post-IPO Discount
Seaport Therapeutics leverages proprietary Glyph technology to enhance bioavailability and safety for CNS drugs, targeting MDD and GAD markets. SPTX maintains a cash runway into 2029, with $427.3 million at June 30, trad
PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgoβ’ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
[url="]PureTech Health plc[/url] (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and tran
Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgoβ’ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
[url="]Seaport Therapeutics, Inc.[/url] (Nasdaq: SPTX) (Γ’ΒΒSeaportΓ’ΒΒ or the Γ’ΒΒCompanyΓ’ΒΒ), a clinical-stage therapeutics company developing novel neuropsychia
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoβ’ in Patients with Generalized Anxiety Disorder and Sleep Disturbance
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Doses First Patient in GlyphAgo Phase 2a Trial in Generalized Anxiety Disorder & Sleep Disturbance.
Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance
BOSTON--(BUSINESS WIRE)--Seaport Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo in Patients with Generalized Anxiety Disorder & Sleep Disturbance.
Seaport Therapeutics (NASDAQ:SPTX) Shares Gap Up β Should You Buy?
Seaport Therapeutics, Inc. (NASDAQ: SPTX - Get Free Report) gapped up before the market opened on Thursday. The stock had previously closed at $18.69, but opened at $20.12. Seaport Therapeutics shares last traded at $19.